glp 1 for iih Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension | The Journal of Headache and Pain The effect of GLP-1 agonist

It should not be used in patients with trimethylaminuria (fish odor syndrome) or carnitine palmitoyltransferase II deficiency

From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper

And then the other thing to consider besides those micronutrients is really focusing on managing side effects

Why Choose Remedy Bone Broth

GLP-1 agonists require caution in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2